Aurora Cannabis’s Q1 2027 Call: U.S. Grower Partnerships vs. Competition and Safari Integration Timelines Clash

Date of Call: Aug 5, 2026

Financials Results

• Revenue: $67.6 million, with international medical cannabis net revenue up 17%
• Gross Margin: 58%, at the high end of the expected annual range

Guidance:

• Revenue and adjusted EBITDA for Q2 expected to be substantially higher than in Q1.
• Fiscal 2027 outlook reaffirmed, reflecting steps to strengthen the business and drive growth in global medical cannabis.

Business Commentary:

International Revenue Growth:

• Aurora Cannabis reported that its international medical cannabis net revenue rose 17% to $43 million, with about 64% of total net revenue generated outside of Canada, up from 50% last year.
• The growth was driven by strong performance in Germany and other international markets, along with strategic acquisitions like the Safari Flower Company to increase manufacturing capacity.

Adjusted Gross Margin and Cost Efficiency:

• The company achieved an adjusted gross margin of 58%, which is at the high end of their expected annual range.
• This was due to strong contributions from international markets and efficiencies in manufacturing, such as improvements in yield and potency through investments in genetics and plant science.

Impact of Canadian Reimbursement Changes:

• Aurora Cannabis experienced an impact on its Canadian medical net revenue due to a 30% reduction in reimbursement rates effective April 1st.
• Despite this, the company maintained strong margins in its international business, which helped offset the changes and supported overall adjusted gross margins.

Cash Position and Strategic Investments:

• The company ended the quarter with nearly $150 million in cash, cash equivalents, and short-term investments, with no debt.
• This strong cash position provides flexibility to navigate regulatory and competitive developments and to make strategic investments in international expansion and capacity enhancement.

Focus on EU GMP Certification and Manufacturing Capacity:

• Aurora's acquisition of the Safari Flower Company and its EU GMP certification added critical manufacturing capacity.
• This aligns with their strategy to meet the growing international demand for high-quality EU GMP products, particularly in Europe, enhancing their competitive position in the medical cannabis market.

Sentiment Analysis:

Overall Tone: Positive

• Management expressed being 'encouraged by our continued strong margins,' 'optimistic in our long-term trajectory,' and 'incredibly excited about the future.' They highlighted strong international growth, a robust balance sheet, and confidence in navigating regulatory challenges.

Q&A:

• Question from Bill Kirk (Roth Capital Partners): Could you give more details on expectations for sequential revenue growth and EBITDA improvement, and any markets or cost savings driving that?
  Response: Growth will come from the same key markets (Germany, Poland, Australia, New Zealand), with confidence driven by continued manufacturing efficiencies and genetic improvements yielding up to 40% better yields.

• Question from Bill Kirk (Roth Capital Partners): What is your view on U.S. growers exporting to international markets and potential competition or partnership with them?
  Response: Sees U.S. entry as difficult due to stringent regulations and supply chain challenges; believes Aurora's integrated, decade-long GMP manufacturing experience is a big advantage, with potential for future partnerships post-rescheduling.

• Question from Fabrico Gomez (ATB Capital Markets): What is the magnitude of pricing pressure in Germany, and how do you see the regulatory environment evolving there?
  Response: Pricing pressure is mainly in the value segment; core and premium segments have held up well. Regulatory changes, similar to Poland, are seen as a challenge that favors established, experienced operators like Aurora.

• Question from Ryan Neal (TD Cowen): Can you isolate the impact of lower reimbursement rates on Canadian medical, and have you seen changes in patient behavior or pricing?
  Response: The 30% reimbursement rate cut on April 1st impacted revenue as expected; patient behavior and pricing have remained largely unchanged as the cost adjustment is absorbed by licensees.

• Question from Ryan Neal (TD Cowen): How is the integration of Safari progressing, and what are the expected synergies for fiscal 2027?
  Response: Integration is going well, with Safari's EU GMP certification a positive. Contributions were seen in Q1, and more details on future accretion and operational/genetic improvements are expected in coming quarters.

• Question from Pablo Zuanek (Zuanek & Associates): What is the natural cap on veteran penetration in Canadian medical, and is there room for further growth?
  Response: It's difficult to define a cap; the system is healthy and Aurora sees share growth opportunities. Veteran interest in medical cannabis is also portable to other international markets.

• Question from Pablo Zuanek (Zuanek & Associates): Have you been slow in the UK market, and can you still catch up given its vertical integration?
  Response: Declines being slow; focus is on genetics and manufacturing, not clinics or pharmacies. High-quality GMP products are valued in the UK self-payer market, and Aurora is confident in its long-term positioning.

• Question from Ryan Neal (TD Cowen): What is recent progress in Australia as you transition to more core and premium offerings?
  Response: Progress is strong in Australia's core and premium segments, with the country offering a broad product range beyond flour and oils. Success in Australia also provides synergies and a jumping-off point for opportunities in New Zealand.

Contradiction Point 1

U.S. Growers as Potential Partners vs. Competitors

Contradiction on whether U.S. growers are primarily competitors or potential partners in international markets.

Bill Kirk (Roth Capital Partners) - Bill Kirk (Roth Capital Partners)

2027Q1: The company sees potential for partnerships, especially as U.S. rescheduling creates opportunities for collaboration similar to existing international partnerships. - Miguel Martin(CEO)

How does the company view U.S. growers exporting to international markets—are they seen as competition or potential partners? - Fabrico Gomez (ATB Capital Markets)

2027Q1: It is still early, but entering markets like Germany with stringent GMP standards is challenging for any operator, whether from the U.S. or Canada. - Miguel Martin(CEO)

Contradiction Point 2

Timeline for Safari Acquisition Benefits

Contradiction on the timeline for realizing the financial benefits from the Safari Flower acquisition.

Pablo Zuanek (Zuanek & Associates) - Pablo Zuanek (Zuanek & Associates)

2027Q1: The integration is going well, and the company saw contributions from Safari in Q1. More details on future impacts will be provided in coming quarters... - Miguel Martin(CEO)

What is the projected upper limit for veteran penetration in the Canadian medical cannabis market, given its increase from 4% to 8% over four years? - Pablo Zuanek (Zuanek & Associates)

2027Q1: Integration is going well, and the acquisition was accretive to adjusted EBITDA in Q1 2027. - Miguel Martin(CEO)

Contradiction Point 3

Expected Impact on Canadian Medical Revenue from Reimbursement Cut

Contradiction on whether the revenue decline from reimbursement cuts is expected to occur in the next fiscal year.

"Ryan Neal (TD Cowen), can you comment on the company's Q2 earnings performance?" - Ryan Neal (TD Cowen)

2027Q1: The impact on Canadian medical revenue was as expected, driven by a 30% reduction in reimbursement rates effective April 1, 2026. - Simona King(CFO)

Can you isolate the impact of lower reimbursement rates on Canadian medical revenue, gross profit, and EBITDA, and have you observed any changes in patient behavior or pricing since the adjustment? - Derek Lessard (TD Cowen)

2026Q4: This is a primary driver of the expected decline in total net revenue... for fiscal 2027. - Miguel Martin(CEO), Simona King(CFO)

Contradiction Point 4

Nature of Primary U.S. Market Opportunity Post-Rescheduling

Contradiction on the main opportunity in the U.S. market post-rescheduling—partnerships or direct entry.

Bill Kirk (Roth Capital Partners) - Bill Kirk (Roth Capital Partners)

2027Q1: Aurora's decade-plus of large-scale GMP manufacturing experience is a significant advantage... sees potential for partnerships... similar to existing international partnerships. - Miguel Martin(CEO)

How does the company view U.S. growers entering international markets as potential competitors or partners? - Frederico Gomes (ATB Capital Markets)

2026Q4: Potential opportunities include: 1) Partnerships for research... 2) Partnerships for GMP manufacturing and distribution... 3) Import/Export opportunities... - Miguel Martin(CEO)

Contradiction Point 5

Timeline and Details for Exiting Canadian Consumer Cannabis

Contradiction on the status and timeline for fully exiting the Canadian consumer cannabis segment.

Bill Kirk (Roth Capital Partners) - Bill Kirk (Roth Capital Partners)

2027Q1: The decision to fully exit consumer cannabis in Canada is being continuously evaluated; the company would consider it if it best suited profitability and growth, though they still maintain a touchpoint in the segment. - Miguel Martin(CEO)

What are the expectations for sequential revenue growth and EBITDA improvement from Q1, and are specific markets or cost-saving opportunities driving this? - Kenrick Tai (Canaccord Genuity)

2026Q3: The company is evaluating the specifics of the exit, but the reallocation of high-quality flower to international markets will significantly benefit financial results. - Miguel Martin(CEO)